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Abstract Dipeptidyl peptidase-4 inhibitors are widely
used in type 2 diabetes. Endothelium plays a crucial role
maintaining vascular integrity and function. Chronic
exposure to high glucose drives to endothelial dysfunc-
tion generating oxidative stress. Teneligliptin is a novel
dipeptidyl peptidase-4 inhibitor with antioxidant proper-
ties. This study is aimed to verify a potential protective
action of teneligliptin in endothelial cells exposed to high
glucose. Human umbilical vein endothelial cells were
cultured under normal (5 mmol/L) or high glucose
(25 mmol/L) during 21 days, or at high glucose during 14
days followed by 7 days at normal glucose, to reproduce
the high-metabolic memory state. During this period,
different concentrations of teneligliptin (0.1, 1.0 and 3.0
µmol/L) or sitagliptin (0.5 µmol/L) were added to cells.
Ribonucleic acid and protein expression were assessed
for antioxidant response, proliferation, apoptosis and
endoplasmic reticulum stress markers. Teneligliptin
promotes the antioxidant response in human umbilical
vein endothelial cells, reducing ROS levels and inducing
Nrf2-target genes messenger ribonucleic acid expression.
Teneligliptin, but not sitagliptin, reduces the expression
of the nicotine amide adenine dinucleotide phosphate
oxidase regulatory subunit P22−phox, however, both blunt
the high glucose-induced increase of TXNIP. Tene-
ligliptin improves proliferation rates in human umbilical
vein endothelial cells exposed to high glucose, regulating
the expression of cell-cycle inhibitors markers (P53, P21
and P27), and reducing proapoptotic genes (BAX and
CASP3), while promotes BCL2 expression. Teneligliptin
ameliorates high glucose-induced endoplasmic reticulum
stress reducing the expression of several markers (BIP,
PERK, ATF4, CHOP, IRE1a and ATF6). Teneligliptin
has antioxidant properties, ameliorates oxidative stress
and apoptotic phenotype and it can overcome the meta-
bolic memory effect, induced by chronic exposure to high
glucose in human endothelial cells.
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Human aortic endothelial cells HAECs.
Human epidermal growth factor hEGF
Human recombinant ﬁbroblast growth factor-
beta
hFGF-b
Human umbilical vein endothelial cells HUVECs
NAD(P)H dehydrogenase quinone-1 NQO-1
NAD(P)H oxidase NOX
Nicotine amide adenine dinucleotide
phosphate
NADPH
Non-fat dried milk NFDM
Normal glucose NG
Nuclear factor (erythroid-derived 2)-like 2 NRF2
Reactive oxygen species ROS
Real-time polymerase chain reaction qRT-PCR
Thioredoxin TRX
Thioredoxin interacting protein TXNIP
Thioredoxin reductase TXNRD
Type 2 diabetes mellitus T2DM
Unfolded protein response UPR
Introduction
Type 2 diabetes mellitus (T2DM) patients have a doubled
risk to suffer from cardiovascular diseases (CVD) compared
to non-diabetic individuals after adjustment for other car-
diovascular risk factors [1]. Substantial clinical and
experimental evidences suggest that endothelial dysfunction
(ED) is a crucial early step in the development of CVD [2].
Continuous exposure to high-glucose levels is accepted as
the major factor implicated in the pathogenesis of diabetic
vascular complications [3]. Several lines of evidence indi-
cate that hyperglycemia causes tissue damage mostly
through reactive oxygen species (ROS) overproduction
[3, 4], increasing oxidative stress and fostering the devel-
opment of ED [3]. However, lowering glucose levels is not
sufﬁcient to switch off this intracellular pro-oxidant envir-
onment [5], a pathogenic mechanism partly explaining the
“metabolic memory” concept, deﬁned like the perpetuation
of vascular damage despite the achievement of improved
glycemic control [6]. In vitro experiments on cultured
endothelial cells (ECs), as well as in vivo studies on diabetic
animals, show a ROS-mediated persistence of vascular
stress after glucose normalization, with long standing mar-
kers of oxidative stress and overactivation of pathways
widely linked to the pathogenesis of ED and diabetic
complications [5].
Glucagon-like peptide 1 (GLP-1) improves endothelial
function in diabetes [7–9], so therapeutic strategies for
patients with T2DM are focused in increasing the incretin
response, either by inhibiting dipeptidyl peptidase-4 (DPP-
4) activity or by using degradation-resistant GLP-1 analo-
gues [7]. DPP-4 is an ubiquitously expressed transmem-
brane glycoprotein that cleaves N-terminal dipeptides from
a variety of substrates [7], including the incretin hormones
GLP-1 and gastric inhibitory polypeptide (GIP).
Among DPP-4i, it is recent the commercialization of the
potent, long-lasting DPP-4i, teneligliptin. It has a unique
structure characterized by ﬁve consecutive rings, explaining
its powerful activity. Teneligliptin has a half-life of 24.2 h,
with resulting DPP-4 inhibition throughout the day, and is
eliminated by hepatic metabolism or excreted from the
kidney as the unchanged drug, meaning that a dose
adjustment is not required, even for patients with renal or
hepatic disorders [10]. The efﬁcacy and safety of long-term
use of teneligliptin in monotherapy or combination therapy
were evaluated in T2DM patients [11]. DPP-4i have shown
an antioxidant capacity [12], however, no studies have
evaluated a possible difference between them, as well as if
this property can impact on HG-induced damage to ECs.
The present study was aimed to explore the effects of the
DPP-4i teneligliptin, compared to sitagliptin, on ED and
antioxidant response in ECs exposed to high-glucose
conditions.
Materials and methods
Cell culture and experimental design
Human umbilical vein endothelial primary cells (HUVECs)
were purchased by Lonza and cultured with EGM™-2
Bulletkit™ (LonzaIbérica S.A.U., Barcelona, Spain) adding
supplemental growth factors: epidermal growth factor,
hydrocortisone, human recombinant ﬁbroblast growth fac-
tor-beta, heparin, 2 % fetal bovine serum and gentamicin/
amphotericin-B, provided with the media, at 37 °C in a
humidiﬁed atmosphere with 5 % CO2. Cells were used
between 4–6 passages. HUVECs were seeded and allowed
to attach overnight. Next day cells were exposed to one of
three glucose experimental conditions with or without
teneligliptin (at 0.1, 1.0 or 3.0 µmol/L) or sitagliptin (at 0.5
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µmol/L) [13]: continuous normal glucose (NG-5 mmol/L)
for 21 days; continuous high glucose (HG-25 mmol/L) for
21 days; and high-metabolic memory (HM-continuous HG
for 14 days, followed by NG for the last 7 days) [6, 14].
HUVECs were cultured during the 3 weeks changing the
media each 48 h and without passaging the cells.
Teneligliptin hydrogen bromide hydrate (3-[(2S,4S)-4-
[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]
pyrrolidin-2-yl-carbonyl]thiazolidinehemipentahydrogen-
bromide hydrate) was kindly provided by Mitsubishi
Tanabe Pharma Corporation (Osaka, Japan).Sitagliptin
phosphate monohydrate (7-[(3R)-3-amino-1-oxo-4-(2,4,5-
triﬂuorophenyl)butyl]-5,6,7,8-tetrahydro-3-(triﬂuoromethyl)-
1,2,4-triazolo[4,3-a]pyrazine phosphate) was provided by
BioVision (San Francisco, USA).
RNA isolation and real-time polymerase chain reaction
(qRT-PCR)
Total RNA was isolated from HUVECs using Total RNA
isolation kit (NorgenBiotek Corp, Thorold, Ontario,
Canada) following the manufacturer’s instructions. First-
strand complementary deoxyribonucleic acid (DNA) was
prepared using 1–2 µg of total RNA, the Superscript III RT
kit and random hexamer primers (Invitrogen, Carlsbad, CA,
USA) in a total volume of 25 µl according to the manu-
facturer’s instructions. Reverse transcription reaction was
carried for 90min at 50 °C and an additional 10min at 55 °C.
Real-time PCR (qRT-PCR) was performed on an ABI
Prism 7900 sequence detection system using Sybr Green
reagents (Takara Bio Company, Clontech, Mountain View,
CA, USA) and TaqMan® Gene Expression Master Mix
(Life Technologies, Madrid, Spain).
Protein analysis
For western blot analysis HUVECs were lysed in Radio-
immunoprecipitation assay buffer (Sigma-Aldrich) adding
10 % proteases and 1% phosphatases inhibitors (Sigma-
Aldrich Química, S.L., Madrid, Spain). Protein content was
determined using Bradford assay buffer (Sigma-Aldrich
Química, S.L., Madrid, Spain). Fifty micrograms of lysates
were separated by electrophoresis using polyacrylamide
gel electrophoresis gels (4–12 %; LonzaIbérica S.A.U.,
Barcelona, Spain) and transferred to a polyscreen poly-
vinylidene diﬂuoride membrane (Perkin Elmer, Waltham,
MA, USA). After blocking with 5 % non-fat dried milk or 5
% bovine serum albumin, membranes were incubated with
the respective primary antibodies—cleaved caspase3
(Asp175) antibody (#9661s) and p21 Waf1/Cip1 (12D1)
antibody (#2947; Cell Signalling Technology)—overnight
at 4 °C. The membranes were then incubated with the
appropriate secondary horseradish peroxidase-conjugated
IgG antibodies (GE Healthcare Europe GmbH, Barcelona,
Spain) at a 1:3,000 dilution for 1 h at room temperature.
Blots were visualized with ECL reagent (Pierce Bio-
technology, Rockford, IL, USA) using a LAS4000 Lumi-
Imager (Fuji Photo Film, Valhalla, NY, USA). β-Actin—
ACTB antibody (A-2066; Sigma-Aldrich Química, S.L.,
Madrid, Spain)—served as the loading control. Protein




The viability of ECs was assessed by the colorimetric MTT
reduction assay. Cells were plated in 96-well plates at a
concentration of 4 × 103cells/well and cultured in NG, HG
or HM conditions for 21 days, with or without teneligliptin/
sitagliptin, changing the media each 48 h. After treatments,
cell medium was removed and replaced with media con-
taining 0.5 mg/ml MTT and then incubated for 4–6 h at 37 °C
in a humidiﬁed atmosphere with 5 % CO2. Formazan
crystals formed were solubilized with 0.04 N HCl in iso-
propanol. The absorbance was measured at 570 nm, with a
reference ﬁlter at 650 nm. The results are presented as mean
± SEM and represent the percentage of control.
5-Bromodeoxyuridine (BrdU) incorporation assay
This method was used to determine the cellular proliferation
with a direct non-radioactive measurement of DNA synth-
esis, based on the incorporation of the pyridine analogous 5
bromo-2′-deoxyuridine (BrDu) instead of thymidine
into the DNA of proliferating cells. BrdU incorporation was
assayed using the Cell Proliferation enzyme-linked immu-
nosorbent assay colorimetric assay (Roche, Mannheim,
Germany) according to the manufacturer’s instructions.
Brieﬂy, HUVECs were grown at 2.5 × 103 at 96-well
plate and cultured in NG, HG or HM conditions for 21 days,
with or without teneligliptin/sitagliptin, changing the media
each 48 h. After this period, cells were labeled overnight
with BrdU, and then they were ﬁxed and washed. Anti-
BrdU-POD working solution and substrate solution were
added, and BrdU incorporation was quantiﬁed by measur-
ing the absorbance at 370 nM in a microplate reader
(Synergy HT, BioTek Instruments, Inc., Winooski,
Vermont, USA).
ROS measurement
The ﬂuorescent probe, 2′,7′-Dichloroﬂuorescein diacetate
(H2DCFDA), was used to measure the intracellular pro-
duction of ROS. In all, 5 × 103 HUVECs were grown on
clear ﬂat bottom treated 96-well plates during 21 days under
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NG, HG or HM conditions. At the end of the experiment,
cells were treated with the indicated drugs, and the reactions
were stopped staining cells with 20 μM H2DCFDA for 30
min at 37 °C. The ﬂuorescence intensity of H2DCFDA was
kinetically measured at an excitation and emission wave-
length of 485 nm and 530 nm for H2DCFDA using a
ﬂuorescent microplate reader (Synergy HT, BioTek Instru-
ments, Inc., Winooski, Vermont, USA.
Statistical analysis
Numerical data were expressed as mean ± SD and they
were analyzed using one-way ANOVA to compare the
means of all the groups. The Bonferroni correction for
multiple comparisons was used to determine which pairs of
means were different. Differences were considered sig-
niﬁcant at p o 0.05.
Results
Chronic teneligliptin treatment at doses between 0.1 and
3.0 µmol/L does not reduce cell viability of HUVECs
We ﬁrstly performed an MTT analysis with the aim to
examine whether HUVECs viability was affected due to
teneligliptin addition at different doses. HUVECs were
maintained for 21 days under different conditions: NG, HG
and HM. During the exposure, teneligliptin was added
chronically to the medium at 0.1, 1.0 or 3.0 μmol/L. We
used as control the DPP-4i sitagliptin at the concentration of
0.5 μmol/L [13].
We did not observe a reduction in cell viability, but
rather an increase, despite of non-signiﬁcant values due to
high variability between experiments at lower doses of the
DPP-4i. Moreover, no differences between the lower tene-
ligliptin doses were identiﬁed (Fig. 1).
Chronic teneligliptin treatment decreases HG-stress
markers in HUVEC cells
We wondered to examine if a reduction of hyperglycemic
stress after DPP-4i treatment existed. Three different markers
of HG stress were then measured (Fig. 2): (1) the ROS; (2)
the subunits Nox4 and P22−phox of the enzyme NAD(P)H
Oxidase, shown to be a source of ROS in the endothelium of
diabetic patients [15]; and (3) the thioredoxin interacting
protein (Txnip), which has been demonstrated to be increased
under hyperglycemia and ROS overproduction [16, 17].
With the aim to assess the effects of teneligliptin on ROS
production, HUVECs were exposed to HG, with or without
glucose normalization, and then loaded with the cell-
permeable ROS-sensitive ﬂuorescent dye H2DCFDA.
As expected, exposure to HG, either sustained or after
normalization, resulted in a signiﬁcant induction of ﬂuor-
escence compared with cells exposed to NG. Teneligliptin
treatment decreased ROS generation levels in those cells
maintained under HG and HM conditions in a dose-
dependent manner (Fig. 2a). A reduction in ROS production
was also reached with sitagliptin, however, a signiﬁcant
difference was observed when HUVECs treated with tene-
ligliptin 3.0 μmol/L were compared with cells treated with
sitagliptin (Fig. 2a). Noteworthy, the efﬁcacy of tene-
ligliptin at 0.1 μmol/L was similar to 0.5 μmol/L sitagliptin,
suggesting a more potent antioxidant property of
teneliglitin.
ROS are constantly produced by all cellular types, and
one of the involved reactions is through NAD(P)H oxidase
(NOX), the predominant source of ROS in the vasculature
[16]. We examined gene expression levels of the essential
subunit NOX4 and the cytosolic regulatory component
P22−phox [18]. The expression of both NOX4 and
P22−phox was induced similarly under HG and HM condi-
tions (Fig. 2b). Teneligliptin decreased only the messenger
RNA (mRNA) of the regulatory subunit P22−phox that was
reduced in a signiﬁcant statistical manner. In contrast,
sitagliptin did not exert any effect in the expression of
NOX4 and P22−phox (Fig. 2b).
TXNIP belongs to the thioredoxin (TRX) pathway,
inhibiting TRX activity in a redox-dependent manner, by
binding its reduced form but not the oxidized one [16].
TRX also has a redox-regulatory activity, playing a role
in controlling signalling pathways that are involved in
ROS production in endothelium [19]. In our cellular
model, TXNIP expression is increased in HG and HM










































































Fig. 1 Teneligliptin effects on HUVECs viability after exposure to high-
glucose conditions. HUVEC cells were incubated during 21 days under
three different glucose conditions: NG (normoglycemia-5 mmol/L),
HG (hyperglycemia-25 mmol/L) and NM (metabolic high-glucose
memory-alternatively 5 and 25 mmol/L). Different doses of tene-
ligliptin (0.1, 1.0 and 3.0 µmol/L) and sitagliptin (0.5 µmol/L) were
used. Cell viability (%) was examined by an MTT assay. Bars
represent mean± SEM for three independent experiments
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damage also in HUVECs, being more pronounced in the
HG state. Teneligliptin, as well as sitagliptin, treatments
were able to counteract TXNIP upregulation, so proving
the positive actions of both DPP-4i on HUVECs exposed
under hyperglycemic conditions without normalization
(Fig. 2c).
Chronic teneligliptin treatment increases heme
oxygenase-1 (HMOX1) gene expression in HUVEC cells
incubated under hyperglycemia
One of the potential targets of ROS, induced by NAD(P)H












































































































































































































































































































Fig. 2 Teneligliptin effects on HG stress markers: ROS, NAD(P)H
oxidase subunits and TXNIP in HUVECs cultured under HG/HM
conditions. HUVECs were maintained under NG, HG or HM condi-
tions during 21 days. During the exposure, teneligliptin was added
chronically to the medium at 0.1, 1.0 or 3.0 μmol/L. We used as control
the DPP-4 inhibitor sitagliptin at the concentration of 0.5 μmol/L.
a ROS production was stained by 20 μM H2DCFDA for 30 min, and
its oxidation product (DCF) ﬂuorescence indicated ROS formation. b,c
Total cellular RNA was isolated from HUVECs and mRNAs encoding
for NOX4, P22−phox and TXNIP genes were assessed by qRT-PCR and
expressed relative to ACTB. *p o 0.05 and **p o 0.01 vs. NG. #p
o 0.05 vs. HG. $p o 0.05 vs. HM. Bars represent mean± SEM for
six independent experiments
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the master regulator of intracellular antioxidant response [16].
We analyzed gene expression levels of: HMOX, NAD(P)H
dehydrogenase quinone-1 (NQO) and thioredoxin reductase
(TXNRD), all described as Nrf2 target genes [16] and we
observed that they responded in a different manner to HG and
HM exposure, with or without DPP-4i treatment (Fig. 3).
In normoglycemia, teneligliptin upregulated HMOX gene
expression in a dose-dependent manner, however, sitaglip-
tin failed to do so. Sustained hyperglycemia exposure
induced the expression of HMOX and NQO mRNA, indi-
cating a possible activation of Nrf2 and the initiation of the
antioxidant cascade. Teneligliptin enhances the antioxidant
response in the higher doses (1.0 and 3.0 µmol/L), while
sitagliptin had no effect, even a non-signiﬁcant reduction in
HMOX. The scenario was different in the HM condition.
Only NQO was increased due to hyperglycemia, however,
neither teneligliptin nor sitagliptin exerted any effect.
Contrary, HMOX expression was reduced with the glucose
normalization but teneligliptin increases its expression, only
at its highest dose (Fig. 3).
Nrf2 controls not only Hmox-1 and Nqo-1 which are
related to ROS detoxiﬁcation process, but also other anti-
oxidants pathways [16]. One of them is the TRX pathway,
which is regulated not only by TXNIP, as described before,
but also by TXNRD [16]. A different expression pattern
was observed for the antioxidant TXNRD, a lower expres-
sion trend was observed by higher doses of teneligliptin in
NG. TXNRD transcript levels were also regulated differ-
ently in chronic hyperglycemia and metabolic memory
conditions: sustained hyperglycemia, but not metabolic
memory state, induced TXNRD gene expression. Contrary
to what expected, chronic teneligliptin treatment not only
did not enhance such increase, but downregulated its gene
expression for the HG state. Only sitagliptin was able to
upregulate TXNRD in a signiﬁcant manner in this condition.
Different regulation was observed in HM, while TXNRD
expression was not affected by the glycemic treatment, there
was a dose-dependent upregulation of gene expression
levels of TXNRD when HUVECs were treated with tene-
ligliptin, reaching signiﬁcance at its highest dose. No effect
was observed after sitagliptin addition (Fig. 3).
Chronic teneligliptin treatment improves proliferative
capacities of HUVEC cells
In order to assess the pro-survival capacities of teneligliptin
in HUVEC cells exposed to sustained HG conditions, gene
expression levels of several markers of cell proliferation and
apoptosis were analyzed: Cdkn1a/p21 (hereafter p21),
Cdkn1b/p27 (hereafter p27), p53, Bcl-2, Bax and caspase 3.
P21, a member of the cyclin-dependent kinase inhibitors
family is a downstream target of p53, it is upregulated
following the persistent generation of ROS and functions as
one of the major determinants of the cellular response to
stress [20]. P21 also has pro-survival functions in response
to oxidative stress by inhibiting the activation of caspase 3,
caspase 9 and other pro-apoptotic factors, preventing cell
death [21]. Some of the mediators of p21 protection system
against hyperglycemia-induced cell death belong to the Bcl-
2 family and, among them, the anti-apoptotic Bcl-2 and the
pro-apoptotic Bax genes [22].
As expected, p53 was increased when HUVECs were
exposed to HG and HM conditions. Teneligliptin treatment
added under these conditions produced a decrease in p53
transcript levels. Sitagliptin had similar effects under the
mentioned conditions (Fig. 4a). Regarding p21 gene
expression, it was increased under HG conditions, and,
contrary to what we expected, it was recovered under HM
























































































































Fig. 3 Teneligliptin effects on the antioxidant gene expression in
HUVECs cultured under HG/HM conditions. Total cellular RNA was
isolated from HUVECs after 21 days in culture in NG, HG or NM.
Cells were treated with different doses of teneligliptin (0.1, 1.0 and 3.0
µmol/L) or sitagliptin (0.5 µmol/L). mRNA encoding for the indicated
genes was assessed by qRT-PCR and expressed relative to GAPDH or
ACTB. *p o 0.05 vs. NG. #p o 0.05 vs. HG. $p o 0.05 vs. HM.
Bars represent mean± SEM of six independent experiments
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under all three conditions: NG, HG and HM. Such decrease
was in a dose-dependent manner, and become statistically
signiﬁcant for the HG and HM states when teneligliptin was
used at the highest concentration of 3.0 μmol/L. Sitagliptin
also downregulated gene expression levels of p21, although
not so important as teneligliptin 3.0 μmol/L did (Fig. 4a).
P21 protein analysis conﬁrmed the above mentioned results.
Hyperglycemia increased P21 protein levels in a trend
manner, and teneligliptin reduces its expression at all doses,
even in normoglycemic condition. Similar observations can
be described with sitagliptin addition (Fig. 4c).
Conversely, P27 expression levels were not affected by
hyperglycemia exposure, however, teneligliptin added at its
highest dose in HG signiﬁcantly decreased p27 mRNA
levels (Fig. 4a).
Regarding the apoptotic pathway, gene expression levels
of the anti-apoptotic BCL2 were increased by teneligliptin
under NG conditions, and the pro-apoptotic gene BAX was
decreased only when HUVECs were treated with tene-
ligliptin 1.0 μmol/L. When ECs were exposed to HG con-
ditions, gene expression levels of BCL2 decreased and, in
accordance, CASP3 was upregulated, similarly to what is
happening in HM (Fig. 4b). Teneligliptin was able to
increase gene expression levels of BCL2 in HG at similar
levels with all doses, and in parallel it decreased BAX and
CASP3 expression in a dose-dependent manner, reaching
signiﬁcance only at the highest dose. Active CASP3 protein
levels were also reduced by all doses of teneligliptin in HG
(Fig. 4c). Not many changes in any of the aforementioned
genes could be observed in HM, despite a reduction in
BCL2, and concordantly in CASP3 mRNA, when tene-
ligliptin was added at 3.0 μmol/L (Fig. 4b). Sitagliptin had
similar or lower effects to those observed for teneligliptin in
these tested proliferation markers.
To conﬁrm these results, next step was to assess if
teneligliptin had effects on the proliferation rates of
HUVECs. To this aim, HUVECs were cultured during 21
days under above mentioned experimental conditions and a
BrdU analysis was performed. As it was expected, a sig-
niﬁcant decrease in the proliferation ratio in HUVECs cul-
tured under chronic HG was observed, which was
attenuated in the HM condition (Fig. 4d). Teneligliptin
treatment signiﬁcantly dose-dependently increased the
proliferation rates of cells maintained in HG, as well as
sitagliptin did. A similar, but non-signiﬁcant, proﬁle of
proliferation stimulation was observed in HUVECs treated
with teneligliptin at HM, but not with sitagliptin (Fig. 4d).
Chronic teneligliptin treatment improves endoplasmic
reticulum (ER) function in HUVEC cells exposed to HG
The pathological role of ER stress in the pathogenesis of
diabetes and hyperglycemia is increasingly recognized [23].
Diabetes induces ER stress in many organs such as pancreas
and liver [24], heart [25], nervous system [26], adipose
tissue and kidney [27].
The ability of cells to respond to perturbations in ER
function is critical for their survival, and chronic or unre-
solved ER stress can lead to apoptosis [16, 28]. We assessed
the expression of ER stress response-related transcripts
under NG, HG and HM conditions in HUVEC cells. As we
previously reported [29, 30], HUVEC cells exposed to HG
and generally to the metabolic high-glucose memory, the
expression of some ER stress markers and unfolded protein
response (UPR) was increased. In HG, we observed an
increase in the gene expression of the chaperon BIP and this
result was in accordance with an increased UPR activity.
Teneligliptin was able to decrease gene expression levels of
BIP at all doses both in HG and HM, even sitagliptin had
any signiﬁcant effect (Fig. 5).
We also checked the gene expression of several down-
stream markers of the three different signalling cascades
described for UPR: Perk, Ire1a and Atf6. Regarding Perk
pathway, we assessed the mRNA expression of PERK, ATF4
and CHOP. Teneligliptin added in NG condition did not affect
mRNA levels of ATF4 or CHOP. However, teneligliptin
treatment was able to reduce PERK gene expression levels
when it was added at 1.0 and 3.0 μmol/L doses. Furthermore,
as expected, all these transcripts were increased both under HG
and HM conditions, even if reaching signiﬁcance in the HG
condition, and this result was in accordance with the published
data based on the demonstration of hyperglycemia-induced
damage in ER homeostasis [24, 25, 31].
HUVECs exposed to HG or HM treated with tene-
ligliptin respond differently for each gene. In HG, down-
regulation due to teneligliptin administration was in a dose-
dependent manner for the genes ATF4 and CHOP, while for
PERK we observed a drastic decrease just for the low doses.
Sitagliptin had no signiﬁcant effect in any of them. In HM,
teneligliptin was efﬁcient in reducing ATF4 and CHOP
expression only at its highest dose, while PERK was
reduced with all. Whereas, sitagliptin had no effect on
CHOP expression in HM, it reduced PERK and ATF4 at
similar levels than teneliglitptin did (Fig. 5).
Teneligliptin reduced IRE1a gene expression in a dose-
dependent manner, being signiﬁcant only at high dose of
teneligliptin. HG and HM conditions also increased IRE1a,
and teneligliptin treatment was able to decrease mRNA
levels in both unhealthy conditions, like sitagliptin did
(Fig. 5). Finally, teneligliptin added in NG did not affect
ATF6 mRNA levels. As in generally observed for the other
transcripts, HG exposure induced an increase in gene
expression levels of ATF6, but no effect was further
observed after glucose normalization. Teneligliptin treat-
ment was able to reduce ATF6 mRNA levels at its highest
dose in HG, while sitagliptin was not (Fig. 5).
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Discussion and conclusion
DPP-4 inhibitors are potent drugs used to treat patients with
T2DM [32]. Inhibition of DPP-4 increases levels of
biologically intact incretins, improving glucose metabolism
through the upregulation of insulin secretion and the sup-
pression of glucagon release [7]. Several preclinical studies

































































































































































































































































































































































































































cardioprotective actions, reducing atherosclerosis, vascular
injury and ED. Incretin-based large-scale clinical trials in
T2DM patients with GLP-1RA demonstrate that GLP-1
receptor agonist, liraglutide, reduced the rates of cardio-
vascular events and death compared to the placebo in
patients with type 2 diabetes who were at high-risk for
cardiovascular events (LEADER trial), although lixisena-
tide, which is the short-acting form, did not show any car-
diovascular beneﬁt in patients with diabetes and a recent
acute coronary syndrome (ELIXA trial) [33]. On the other
hand, the outcome studies (SAVOR-TIMI53, EXAMINE
and TECOS) demonstrated no cardiovascular beneﬁt in
patients treated with DPP-4i, although cardiovascular safety
was not compromised [34–36]. In contrast, the newly
published results of the SPEAD-A study, in which T2DM
patients without CVD history treated with alogliptin,
showed a reduced progression of the carotid intima-media
thickness in treated patients [37]. A recent study evidences
the discrepancy between preclinical and clinical data using
these drugs, like DPP-4i, presumably due to the usage of
different experimental models that give rise to diverse and
sometimes non-correlated effects [32]. So, these results
highlighted the need to gain further insights on the mole-
cular mechanisms of DPP-4i, before they can induce
changes in current clinical practice. Moreover, the synthesis
of new agents, as well as longer follow up for complications
development could lead to different results. It may be that
new agents, which more powerful ancillary actions may
show different results.
Teneligliptin has different structure and pharmacody-
namics characteristics from other gliptins, features that could
confer properties diverse from or additive to other DPP-4i.
First, it is a potent, selective and long-lasting inhibitor of
DPP-4 and exhibits strong inhibitory activity via its J-shaped
structure and ‘anchor lock domain’. The second important
feature is that teneligliptin has high tissue distribution [38],
which may be because of its hydrophobic property. Since
DPP-4 is expressed in various tissues, including vasculature,
this might explain teneligliptin pleiotropic effect [10], as
well as its putative protective role in CVD.
In addition to its DPP-4 inhibitory activity, teneligliptin
has radical scavenging properties and showed to normalize
the increased levels of 8-hydroxy-2-deoxyguanosine in
urine, kidney and aorta of diabetic rats [39]. Another study
[40] demonstrated that long-term treatment with tene-
ligliptin signiﬁcantly improves endothelial function in an in
vivo model of spontaneously hypertensive stroke prone rats
that exhibit insulin resistance and glucose intolerance.
Recently, it has been shown that 24-week teneligliptin
treatment improves endothelial function by reactive hyper-
emia index, by reducing the oxidative stress markers reactive
oxygen metabolites (ROMs), measured by the d-ROMS test,
8-hydroxy-2′-deoxyguanosine (8-OHdG) and the urinary
liver-type fatty acid-binding protein in patients with T2DM
and chronic kidney disease, compared to patients who had
received sitagliptin for at least 12 months prior to switching
to teneligliptin. On the other hand, glucose-lowering effect
was not signiﬁcantly different between the two groups [41].
This study suggests that the antioxidative and renoprotective
effects of teneligliptin might be stronger than those observed
with other DPP-4 inhibitors, particularly sitagliptin, which
might be independent of blood glucose-lowering effect.
The main ﬁndings of the present study are:
(i) Teneligliptin has antioxidant properties under NG
in HUVECs, reducing ROS levels and initiating the
transcriptional cascade of the antioxidant genes;
(ii) HG and HM conditions cause a decrease in prolifera-
tion in HUVEC cells, and teneligliptin has the ability
to recover these capacities;
(iii) ER function is impaired due to HG and HM
conditions; teneligliptin can ameliorate it and improve
ER homeostasis.
As far as we know, this is the ﬁrst time that a direct
action of a DPP-4i on ROS production is described in an
endothelial cellular model. Other studies described the
capacity of DPP-4i, sitagliptin or alogliptin, to counteract
ROS production, in other experimental model: such as the
ApoE−/− mice [41, 42]. Here, we demonstrated that tene-
ligliptin at all used doses, and in a dose-response manner, is
able to restore ROS production levels impaired by either
HG or HM detrimental conditions. It is noteworthy that
teneligliptin has a better effect than sitagliptin counteracting
ROS production, even at low doses, meaning a powerful
action of teneliglitptin improving the redox state of ECs.
The novelty of this study is to show how teneligliptin
initiates the antioxidant transcriptional cascade at mRNA
level in an endothelial cellular in vitro model, promoting the
Fig. 4 Teneligliptin effects on proliferation in HUVECs cultured under
HG/HM conditions. HUVECs were maintained under NG, HG or HM
conditions during 21 days. During the exposure, teneligliptin was
added chronically to the medium at 0.1, 1.0 or 3.0 μmol/L. We used as
control the DPP-4 inhibitor sitagliptin at the concentration of 0.5 μmol/
L. a,b Total cellular RNA was isolated from HUVECs and mRNAs
encoding for NOX4 and P22−phox genes were assessed by qRT-PCR
and expressed relative to GADPH or ACTB. c Protein expression of
CASPASE 3 and P21 was assessed by western blot. The panels show a
representative image of different independent experiments. Densito-
metric values were normalized to ACTB and represented relative to the
control cells (NG), normalized to 1. d HUVECs proliferation was
examined by measuring BrdU incorporation. *p o 0.05 and **p o
0.001 vs. NG. #p o 0.05 and ##p o 0.001 vs. HG. $p o 0.05 and $
$p o 0.001 vs. HM. Bars represent mean± SEM for six independent
experiments
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expression of Nrf2 target genes such as HMOX, NQO or
TXNRD, and normalizing the levels of TXNIP which is
upregulated by HG. Strikingly, differently from sitagliptin,
teneligliptin is able to induce the antioxidant Nrf-2-related
transcriptional cascade, even under HG and HM conditions.
The effect of hyperglycemia-induced ER dysfunction has
become a focus of increasing research. The ER is a dynamic
tubular network that participates, among its various actions,
in the maturation and the proper folding of proteins [14].
ER dysfunction has been proposed as one of the causes of
β-cell loss of function [40], and damage in other tissues,
such as the adipose tissue [41, 42], the liver [43] and the
cardiovascular system [44].
Our cellular model conﬁrms that HUVECs cultured
under HG and HM conditions have an increased gene
expression of several ER markers. Novelty, we showed that
the DPP-4i teneligliptin lowers the expression of these ER
stress markers in HUVECs cultured in NG. Moreover, it
counteracts negative effects produced when ECs are
exposed to HG with or without normalization. When the
UPR mechanism fails leading to the continuous accumula-
tion of unfolded proteins, and the cell is not able to re-
establish ER homeostasis, the apoptotic cascade is initiated
through the activation/inactivation of Bcl-2 family members
[16]. As expected, HG lowers cell proliferation rate and
increases apoptosis. Teneligliptin added at NG does not
induce any change in proliferation, however, when it is
added under HG or HM states, it is able to counteract the
apoptotic phenotype induced by hyperglycemia restoring








































































































































































































Fig. 5 Teneligliptin effects on ER function in HUVECs cultured under
HG/HM conditions. HUVECs were maintained under NG, HG or HM
conditions during 21 days. During the exposure, teneligliptin was added
chronically to the medium at 0.1, 1.0 or 3.0 μmol/L. We used as control
the DPP-4 inhibitor sitagliptin at the concentration of 0.5 μmol/L.
Total cellular RNA was isolated from HUVECs and mRNAs encoding
for the different ER stress markers were assessed by qRT-PCR and
expressed relative to ACTB. *p o 0.05 and vs. NG. #p o 0.5 vs. HG.
$p o 0.5 vs. HM. Bars represent mean ± SEM for six independent
experiments
Endocrine
are widely used in the vasculature studies, they are distinct
from ECs relevant to adult T2DM in terms of vascular bed-
umbilical vein vs. arteries and arterioles or higher pro-
liferation rate compared to adult ECs such as human aortic
endothelial cells (HAECs). Therefore, further studies need
to be addressed to conﬁrm these results in other cellular and
speciﬁc in vivo models.
In conclusion, this study suggests that long-term treat-
ment with the DPP-4 inhibitor teneligliptin can induce
antioxidant-response increasing the expression of NRF2
targets, with consequent oxidative stress amelioration and
decrease in ROS production. Moreover, teneligliptin has a
protective role reducing HG-induced ER stress, promoting
cellular recovery, measured as attenuated apoptosis and
increased proliferation rate.
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